The table below shows Candel Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$18.04M
-$8.62M
-$8.44M
-$10.82M
-$8.05M
-$5.63M
Capital expenditure
$675.00K
$3.00K
$7.00K
$138.00K
$171.00K
$229.00K
Investing cash flow
-$675.00K
-$3.00K
-$7.00K
$19.00K
-$171.00K
-$229.00K
Dividends paid
-
-
-
CADL operating cash flow (10-K history)
Candel Therapeutics, Inc. reported operating cash flow of -$38.31M for fiscal year 2025. That is down 41.8% from -$27.02M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from -$9.07M (FY 2020) to -$38.31M. Figures come from the company's audited annual reports as filed with the SEC.